VivoSim Labs, Inc. operates as a biotechnology firm primarily focused on developing three-dimensional tissue models engineered to accurately replicate key characteristics of human diseases. At the core of their operations is an advanced 3D human tissue platform. This innovative system incorporates their exclusive NovoGen Bioprinters—automated instruments designed to fabricate living 3D tissues from mammalian cells—along with supporting technologies crucial for formulating bio-inks and bioprinting intricate multicellular structures. The company's primary therapeutic candidate, FXR314, is currently in a phase 2/3 clinical trial addressing inflammatory bowel disease, with a specific focus on ulcerative colitis. Additionally, FXR314 has successfully concluded a phase 1 clinical trial for liver fibrosis, targeting steatohepatitis. VivoSim Labs fosters research collaborations with esteemed academic partners, including Yale School of Medicine, the Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia, all centered around enhancing their NovoGen Bioprinters. Established in 2007 and headquartered in San Diego, California, the company previously operated under the name Organovo Holdings, Inc. before rebranding to VivoSim Labs, Inc. in April 2025.